A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) (EPCORE™DLBCL-1)

  • End date
    May 13, 2024
  • participants needed
  • sponsor
Updated on 13 October 2022
Genmab A/S Trial Information
Primary Contact
Research And Innovation (0.0 mi away) Contact
+236 other location


The drug that will be investigated in the study is an antibody, epcoritamab, also known as GEN3013 . Since the safety and tolerability of epcoritamab has already been studied in previous studies in humans, the main purpose of this study is to evaluate efficacy. To evaluate this, half of the participants who are eligible will receive epcoritamab and the other half will receive a pre-specified investigator's choice of chemotherapy. Epcoritamab will be studied in R/R DLBCL participants who did not respond to a previous autologous stem cell transplant (ASCT) or do not meet the criteria for ASCT


The trial is an open label, multi-center, global phase 3 randomized trial of Epcoritamab, GEN3013. The goal of this randomized trial is to evaluate the efficacy of epcoritamab (GEN3013 DuoBody®-CD3xCD20) compared to investigator's choice of chemotherapy, in patients with relapsed, refractory diffuse large B-Cell Lymphoma who have failed or are ineligible for high-dose chemotherapy and autologous stem cell transplant (HDT-ASCT). No change in chemotherapy is permitted for participants during the treatment phase of the trial.

Condition Diffuse Large B-cell Lymphoma
Treatment Investigator's Choice Chemotherapy, Epcoritamab
Clinical Study IdentifierNCT04628494
Last Modified on13 October 2022


Yes No Not Sure

Inclusion Criteria

Relapsed or refractory disease and previously treated with at least 1 line of systemic antineoplastic therapy including anti-CD20 mAb-containing combination chemotherapy since lymphoma diagnosis
One of the confirmed histologies below with CD20-positivity
DLBCL, NOS, including de novo or histologically transformed from FL
Double-hit" or "triple-hit" DLBCL (technically classified in WHO 2016 as HGBCL, with MYC and BCL2 and/or BCL6 translocations), including de novo or histologically transformed from FL
FL Grade 3B
ECOG PS score of 0-2
T-cell/histiocyte-rich large B-cell lymphoma
Failed previous HDT-ASCT or not eligible for HDT-ASCT at screening
Patients must have detectable disease by PET scan and measurable by CT scan or MRI
Acceptable renal and liver function
Life expectancy >2 months on SOC treatment

Exclusion Criteria

Any prior therapy with a bispecific antibody targeting CD3 and CD20
Primary Central Nervous System (CNS) tumor or known CNS involvement
Major surgery within 4 weeks prior to randomization
Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to randomization
ASCT within 100 days of randomization
Any investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to randomization
Seizure disorder requiring anti-epileptic therapy
Treatment with CAR-T therapy within 100 days prior to randomization
Clinically significant cardiac disease
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note